Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies

B. J. Bolwell, B. Pohlman, L. Rybicki, R. Sobecks, R. Dean, J. Curtis, S. Andresen, A. Koo, V. Mineff, M. Kalaycio, J. W. Sweetenham

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells ('super mobilizers') have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkin's lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. Two hundred and three patients were super mobilizers, while 147 collected between 2.0 and 7.95 CD3+ cells/kg. Super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens (80 versus 63%, P>0.001). Median CD34+ cell dose for the super mobilizing group was 13.7 × 106 versus 4.4 × 106/kg in the standard collecting group. The super mobilizer group had a superior overall survival (P=0.006). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival. We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown.

Original languageEnglish (US)
Pages (from-to)437-441
Number of pages5
JournalBone Marrow Transplantation
Volume40
Issue number5
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Cell Count
Survival
Neoplasms
Transplants
Autologous Transplantation
Cell Transplantation
Etoposide
Hodgkin Disease
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. / Bolwell, B. J.; Pohlman, B.; Rybicki, L.; Sobecks, R.; Dean, R.; Curtis, J.; Andresen, S.; Koo, A.; Mineff, V.; Kalaycio, M.; Sweetenham, J. W.

In: Bone Marrow Transplantation, Vol. 40, No. 5, 01.09.2007, p. 437-441.

Research output: Contribution to journalArticle

Bolwell, B. J. ; Pohlman, B. ; Rybicki, L. ; Sobecks, R. ; Dean, R. ; Curtis, J. ; Andresen, S. ; Koo, A. ; Mineff, V. ; Kalaycio, M. ; Sweetenham, J. W. / Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. In: Bone Marrow Transplantation. 2007 ; Vol. 40, No. 5. pp. 437-441.
@article{008b29a8f8cb4c9da87cdf33f186b51b,
title = "Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies",
abstract = "The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells ('super mobilizers') have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkin's lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. Two hundred and three patients were super mobilizers, while 147 collected between 2.0 and 7.95 CD3+ cells/kg. Super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens (80 versus 63{\%}, P>0.001). Median CD34+ cell dose for the super mobilizing group was 13.7 × 106 versus 4.4 × 106/kg in the standard collecting group. The super mobilizer group had a superior overall survival (P=0.006). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival. We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown.",
author = "Bolwell, {B. J.} and B. Pohlman and L. Rybicki and R. Sobecks and R. Dean and J. Curtis and S. Andresen and A. Koo and V. Mineff and M. Kalaycio and Sweetenham, {J. W.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1038/sj.bmt.1705763",
language = "English (US)",
volume = "40",
pages = "437--441",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies

AU - Bolwell, B. J.

AU - Pohlman, B.

AU - Rybicki, L.

AU - Sobecks, R.

AU - Dean, R.

AU - Curtis, J.

AU - Andresen, S.

AU - Koo, A.

AU - Mineff, V.

AU - Kalaycio, M.

AU - Sweetenham, J. W.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells ('super mobilizers') have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkin's lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. Two hundred and three patients were super mobilizers, while 147 collected between 2.0 and 7.95 CD3+ cells/kg. Super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens (80 versus 63%, P>0.001). Median CD34+ cell dose for the super mobilizing group was 13.7 × 106 versus 4.4 × 106/kg in the standard collecting group. The super mobilizer group had a superior overall survival (P=0.006). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival. We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown.

AB - The cellular composition of an autologous graft may influence autologous stem cell transplantation (ASCT) outcome. Etoposide (VP) plus filgrastim (G) frequently mobilizes high numbers of CD34+ cells for autologous transplantation. We investigated whether patients collecting high numbers of CD34+ cells ('super mobilizers') have a better outcome than other patients. We reviewed 350 consecutive adult patients with NHL or Hodgkin's lymphoma receiving an ASCT from January 1994 to December 2005, mobilized with VP+G. Super mobilizers were defined as collecting a minimum of 8 × 106 CD3+ cells/kg. Two hundred and three patients were super mobilizers, while 147 collected between 2.0 and 7.95 CD3+ cells/kg. Super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens (80 versus 63%, P>0.001). Median CD34+ cell dose for the super mobilizing group was 13.7 × 106 versus 4.4 × 106/kg in the standard collecting group. The super mobilizer group had a superior overall survival (P=0.006). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival. We conclude that patients had an improved ASCT outcome if large numbers of CD34+ cells were mobilized and infused. The explanation for this observation is unknown.

UR - http://www.scopus.com/inward/record.url?scp=34548091639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548091639&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705763

DO - 10.1038/sj.bmt.1705763

M3 - Article

C2 - 17618321

AN - SCOPUS:34548091639

VL - 40

SP - 437

EP - 441

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -